← Eichor
Study identifier: NCT06514573 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Butyrate Supplementation in Children With Autism Spectrum Disorder (ASD) and Functional Gastrointestinal Disorders

Condition: Autism Spectrum Disorder (ASD)  ·  Sponsor: Istituto Superiore di Sanità

PhaseNA
Planned participants128
Who can joinAll sexes, 3 Years to 6 Years
Healthy volunteersNo

About this study

Autism spectrum disorder (ASD) is a neurodevelopmental condition occurring in 1:77 Italian children. Several comorbidities are reported, including functional gastrointestinal disorders (FGIDs) present in up to 70% of patients. FGIDs are disorders resulting from a combination of symptoms affecting motility, hypersensitivity, and other functions, which are not caused by anatomic or organic origin and that impact the severity of ASD core symptoms and complicate the clinical management of ASD children, especially those who are non-verbal. Evidence reports gut microbiome (GM) remodelling in ASD children, and postbiotic butyrate, a GM-derived metabolite, attenuates FGIDs in children and restores social behavior in ASD mouse models. Clinical data on butyrate effects in ASD are still scanty. The present study investigates the therapeutic effects of a 16-week oral postbiotic supplementation on clinical/behavioral profiles, gastrointestinal disturbances, gut microbiome, and immune and inflammatory biomarkers in peripheral blood and fecal samples in children with ASD and FGIDs. Using the Machine Learning (ML) approach, a subset of artificial intelligence, this study also aims to identify predictive factors implicated in the effect of the postbiotic supplementation on FGIDs, important for prevention through modulation of the microbiota. The investigators expect that treating FGIDs will have an impact on the behavioral and core symptoms of ASD and the quality of life of children and their…

This description comes directly from the study's public registry record.

Talk to the study team

Maria Luisa Scattoni, Ph.D.  ·  +39 0649903104  ·  marialuisa.scattoni@iss.it

Maria Puopolo, MSc  ·  +39 0649903087  ·  maria.puopolo@iss.it

Always discuss trial participation with your own doctor first.

Locations (3)

Azienda Ospedaliera Universitaria Federico IINaples, ItalyRecruiting
Policlinico Tor Vergata HospitalRome, ItalyRecruiting
Istituto Superiore di SanitàRome, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06514573